about
The impact of GPCR structures on pharmacology and structure-based drug designBeyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteinsCapturing Biological Activity in Natural Product Fragments by Chemical SynthesisProtein flexibility in docking and surface mappingMinimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase InhibitorsComprehensive Mechanistic Analysis of Hits from High-Throughput and Docking Screens against β-LactamaseFragment-Based Screen against HIV ProteaseA Small-Molecule Probe Induces a Conformation in HIV TAR RNA Capable of Binding Drug-Like FragmentsDissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein InterfaceExperimental and computational active site mapping as a starting point to fragment-based lead discoveryFragment-Based Screening for Inhibitors of PDE4A Using Enthalpy Arrays and X-ray CrystallographyOvercoming the Limitations of Fragment Merging: Rescuing a Strained Merged Fragment Series TargetingMycobacterium tuberculosisCYP121Integrated biophysical approach to fragment screening and validation for fragment-based lead discoveryIdentification and Optimization of PDE10A Inhibitors Using Fragment-Based Screening by Nanocalorimetry and X-ray CrystallographyApplication of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121Identification and characterization of an allosteric inhibitory site on dihydropteroate synthase.Hitting the target: fragment screening with acoustic in situ co-crystallization of proteins plus fragment libraries on pin-mounted data-collection micromeshes.Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping StrategyA cautionary tale of structure-guided inhibitor development against an essential enzyme in the aspartate-biosynthetic pathwayLarge scale meta-analysis of fragment-based screening campaigns: privileged fragments and complementary technologiesFragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin: Fragment-Based Drug Design Facilitated by Dynamic Combinatorial ChemistryKinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures surveySmall molecule inhibits activity of scavenger receptor A: Lead identification and preliminary studiesComputational fragment-based binding site identification by ligand competitive saturationCapturing nature's diversityChemical Proteomic Profiling of Human MethyltransferasesACFIS: a web server for fragment-based drug discoveryA linear relationship between crystal size and fragment binding time observed crystallographically: implications for fragment library screening using acoustic droplet ejection.Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS targetFragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium.A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Diversity-oriented synthesis: exploring the intersections between chemistry and biology.Fragment approaches in structure-based drug discoveryNovel inhibitors of anthrax edema factor.Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino AcidsAutomated clustering of probe molecules from solvent mapping of protein surfaces: new algorithms applied to hot-spot mapping and structure-based drug design.The Seattle Structural Genomics Center for Infectious Disease (SSGCID).Fragment screening of infectious disease targets in a structural genomics environmentTargeting metalloproteins by fragment-based lead discovery.
P2860
Q24628661-075BACAA-A30E-4A42-97D4-7BDFB50A6FF6Q24649147-CE0CAB6E-8DF1-4AE1-8974-A81A1DB1289DQ26772873-67998952-75B7-4ABA-ADF9-37DEEBF76E19Q26864013-2095AA30-0114-40F7-8612-91DE92B6E862Q27649995-43C3E10E-8B2C-4C78-ADF9-2B330183D031Q27650049-475F967B-94A5-4A27-97B4-D7E7A399073AQ27663595-DFFCD365-E4E7-4D15-91EC-7D9B1C5E4997Q27670818-C1D19C88-42A4-44AA-BB00-F822A5C7C8B2Q27674729-6DC03E93-5C05-497E-B1D5-7331302B3147Q27676521-50A11584-B3B7-446F-8CFB-92E99C8CD3CCQ27676592-77F50B6E-6B94-4366-80B4-F520BBC813ACQ27678718-2586DE9F-DE12-44D0-89B1-D67D3B44FA8EQ27679154-35C2DD5B-224D-4E14-9FA6-3F9E39CB2373Q27681131-ED66ECB8-BADA-42E3-A1DD-777335534810Q27681973-0FF90AAE-D71C-431B-94DF-4052F6615597Q27682349-BA433D0F-3AF2-4277-B330-07F434102B19Q27683710-EDD43C9C-D712-49D7-916C-8B8952097307Q27684168-DD8DBB0F-F6A7-478E-A613-4F2F9DD085A8Q27696319-0EDBA5A6-6954-4F16-9950-2B8D2E06C0F8Q27697268-C111DB3F-F593-437F-B4D7-0A5F4F2E4887Q27718399-D564D7B3-8C46-4F51-967D-37CDA7DE9A07Q28072198-9AA506D8-F65D-4176-A585-0BF20DCE9529Q28397940-9350592D-2E98-4F3D-A257-843C4994CD16Q28475699-F6C1406A-ACB3-40C9-9621-8FC3D1BF2FC5Q28546640-5B34077E-E3C1-4A63-974D-CD64F990E23FQ28821490-BD48DADB-81FF-425D-86BE-4B0C9A95572EQ28830078-D176A06A-3DF4-4F42-A9A4-DAAC05218F88Q30435246-BEF5B131-BA2D-4727-9335-39ACF06912FCQ30452210-38DEE14E-61B0-486D-97B8-0C944206CC3FQ30904604-B8C14AE9-3DC6-4A1D-AF94-7CE2A6DF7E87Q31145317-742CD09A-9A7B-4D71-9CED-9AC08E58E9A7Q33230098-BB0FF47F-5CBC-465E-8169-F2DC0ADB7465Q33231454-5A21D46D-0FB9-4356-A849-F05F0839DEABQ33329074-86E9589E-1EE8-4C20-9224-1840312E1835Q33351165-9418676C-4B66-4DCB-831A-155CA26692CCQ33397357-0C95FDBA-49F1-433B-B566-9B7D73A49683Q33797738-24B2D8CF-2A5D-4CAA-AC9B-EAA9A0B91F0BQ33802114-B44ED2A6-1F61-46A2-964F-F990E7026AC0Q33836468-7B15A6C4-80C6-476C-BC08-DA674AF67FDEQ33896509-862A5D7B-E454-4D3B-BAD9-FB567711702D
P2860
description
article
@en
im Juli 2004 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2004
@uk
ലേഖനം
@ml
name
Fragment-Based Drug Discovery
@en
Fragment-Based Drug Discovery
@nl
type
label
Fragment-Based Drug Discovery
@en
Fragment-Based Drug Discovery
@nl
prefLabel
Fragment-Based Drug Discovery
@en
Fragment-Based Drug Discovery
@nl
P356
P1476
Fragment-based drug discovery
@en
P2093
Daniel A Erlanson
Robert S McDowell
P304
P356
10.1021/JM040031V
P407
P577
2004-07-01T00:00:00Z